Healthcare Business Review: Questcor Defended, Watson’s Recall

Shares of Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR) stay steady after Wednesday’s plummet of almost 50 percent, while Roth Capital joins analysts who now say that the reaction to the Aetna, Inc. (NYSE:AET) situation was “overblown.” The firm’s conference call Thursday “indicated that a highly-engaged and well-prepared reimbursement practice by Questcor has been successful and likely would continue as most cases are tightly sealed and more difficult for denial by insurers.”

Don’t Miss: Pfizer: Here’s How We are Combating Generic Drugs.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) reports an FDA approval of Eylea Injection for the treatment of macular edema. The decision was based on data from Phase 3 studies which indicated that results for Eylea were superior to those for the control group for the primary endpoint.

Watson Pharmaceuticals Inc. (NYSE:WPI) has issued a voluntary recall for two lots of Hydrocodone Bitartrate and APAP Tablets, explaining it’s possible that some tablets surpass the weight specification and also could contain higher than indicated amounts of the ingredients Hydrocodone Bitartrate and/or Acetaminophen.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>